DHR vs QGEN: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
DHR is the larger of the two ($157.25B market cap): the incumbent the market prices for continued execution (23.98x forward earnings, beta 0.80). QGEN is the smaller challenger ($10.22B), cheaper on forward earnings (18.54x): more room to run, but more to prove. If you believe DHR earns its premium (23.98x forward earnings, so the market expects more from it), DHR fits. If you believe in paying less for profit, QGEN fits at 18.54x.
DHR vs QGEN: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | DHR | QGEN | What it tells you |
|---|---|---|---|
| Market cap | $157.25B | $10.22B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 23.98 | 18.54 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 37.01 | 26.75 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.80 | 0.56 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 76% of range | 67% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.93 | 2.94 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: QGEN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how DHR and QGEN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DHR and QGEN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DHR and QGEN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Danaher Corporation (DHR) do?
Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). A large share of revenue is recurring consumables and service tied to installed instruments and ongoing drug manufacturing, which is the core of the investment appeal. Danaher runs the well-known Danaher Business System, a continuous-improvement operating model it uses to drive margins and integrate acquisitions.
What does QIAGEN (QGEN) do?
QIAGEN makes the consumables and instruments labs use to collect, stabilize, purify, and analyze DNA and RNA, then extends into molecular diagnostics through platforms like QIAstat-Dx (syndromic infectious-disease testing), QuantiFERON (latent tuberculosis detection), and QIAcuity digital PCR. It serves more than 500,000 customers across molecular diagnostics, applied testing, academic research, and pharma, with a portfolio of 500-plus proprietary consumables and automated workflows. The December 2025 acquisition of Parse Biosciences pushed its Sample technologies franchise into single-cell analysis, one of five strategic growth pillars the company is steering toward its 2028 goals.
DHR vs QGEN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- DHR drivers: Bioprocessing recovery; Recurring consumables and razor-and-blade mix.
- QGEN drivers: QIAstat-Dx syndromic testing; Sample technologies and single-cell.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s, and was about 37x on GAAP earnings with a forward P/E near 24x as of November 20, 2026), leaving little room for disappointment. For QGEN, quantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings.
DHR or QGEN: which should you pick?
If the story you believe is DHR's (Bioprocessing recovery), DHR is the more direct way to own it; if it is QGEN's (QIAstat-Dx syndromic testing), QGEN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DHR and QGEN guides.
DHR vs QGEN: the full fundamentals
DHR. Danaher grew 2025 revenue about 2.9% to ~$24.6B with ~2% core growth, and growth picked up to about 5.5% in the second quarter of 2026 and about 8.3% in the third. The stock trades near 24x forward earnings and about 22x EV/EBITDA as of November 20, 2026, within its usual premium range, with consensus EPS of about $8.59 for 2026 and $9.32 for 2027. The 21 analysts tracked by Yahoo Finance hold a strong buy consensus with a mean target near $260, about 16% above the latest close; figures are approximate.
QGEN. At ~$10.2 billion and ~19x forward earnings, QGEN is valued as a steady compounder: consensus has 2026 adjusted EPS at ~$2.49 on ~$2.14 billion of sales, rising to ~$2.67 in 2027 on ~7% revenue growth. The stock has re-rated since mid-2026 (up ~13% over three months and ~9% in 2026) after two quarterly beats and the Barclays upgrade, and analysts' average target of ~$49.77 now sits almost exactly at the ~$49.46 price. The valuation reflects durable consumable revenue and margin discipline against low-single-digit organic growth.
Headline figures (approximate, November 2026): DHR shows revenue (ttm) ~$25.6B; Q3 2026 ~$6.55B (+8.3%), q3 2026 adj. eps $2.11 vs ~$1.92 estimate, margins (ttm) ~59.4% gross, ~22.0% operating, ~16.9% net, net income (ttm) ~$4.29B (GAAP EPS ~$6.04); QGEN shows revenue (ttm) ~$2.1B (sales growth ~2.9% YoY in Q3 2026), latest quarter (q3 2026) Sales ~$548M (+2.9% YoY); adjusted EPS $0.65 vs ~$0.63 expected, margins (gross / operating, ttm) ~67% / ~27%, net income (ttm) ~$385M.
The bottom line: DHR vs QGEN
DHR and QGEN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined DHR and QGEN exposure against your real portfolio. It is not an investment adviser.
Wondering how DHR or QGEN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Danaher Corporation
Ask Walnut's AI anything about DHR and see how it fits what you own.
FAQ
What is the difference between DHR and QGEN?
+
Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). QIAGEN makes the consumables and instruments labs use to collect, stabilize, purify, and analyze DNA and RNA, then extends into molecular diagnostics through platforms like QIAstat-Dx (syndromic infectious-disease testing), QuantiFERON (latent tuberculosis detection), and QIAcuity digital PCR. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is DHR or QGEN the better stock?
+
Neither is universally better. DHR is the larger incumbent; QGEN is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, DHR or QGEN?
+
On forward P/E (as of November 2026), DHR trades at 23.98x and QGEN at 18.54x, so QGEN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both DHR and QGEN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of DHR vs QGEN?
+
DHR: Valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s, and was about 37x on GAAP earnings with a forward P/E near 24x as of November 20, 2026), leaving little room for disappointment. Core revenue growth has been slow, around 2% for 2025 and roughly flat in early 2026, so the thesis leans heavily on the bioprocessing recovery arriving on schedule. Biopharma and academic funding cycles, hospital and diagnostics testing volumes, and currency swings all move results. China demand and policy, along with broader biotech funding conditions, are additional swing factors. As a diversified conglomerate, weakness in any one segment can offset strength elsewhere. The shares gave back ground after the third-quarter beat, which shows that strong prints are already expected at this valuation. Total debt of about $27.8 billion against about $5.7 billion of cash is manageable for a company of this size but limits how large the next acquisition can be without more borrowing. QGEN: QuantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings. A large share of revenue tracks academic, pharma, and life-sciences research budgets, which softened in the U.S. and remain sensitive to funding cycles. Roughly half of sales are outside the U.S., so currency moves materially affect reported results (reported growth outpaced constant-currency growth in Q1 2026). QIAGEN competes against much larger, better-capitalized rivals, and guidance cuts have shown the top line is vulnerable to demand shocks: even after a firmer September quarter, sales grew only ~2.9% year over year, and consensus for 2027 is ~7% revenue growth. Net debt is real (~$1.65 billion of debt against ~$833 million of cash), though manageable against ~$751 million of trailing EBITDA. QIAGEN itself has flagged new pressures on global tuberculosis programs, which matter directly to QuantiFERON demand. A change of CEO, with Jonathan M. Pratt succeeding Thierry Bernard, can bring shifts in strategy or priorities, and integration of acquisitions like Parse Biosciences carries execution risk.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DHR or QGEN; figures are approximate and dated (as of November 2026). Verify current data before investing.